# A Clinical Trial of A COVID-19 Vaccine Named Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)

> **NCT04566770** · PHASE2 · COMPLETED · sponsor: **CanSino Biologics Inc.** · enrollment: 480 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
- **BIOLOGICAL:** Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) -placebo

## Key facts

- **NCT ID:** NCT04566770
- **Lead sponsor:** CanSino Biologics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-24
- **Primary completion:** 2021-09-21
- **Final completion:** 2022-01-19
- **Target enrollment:** 480 (ACTUAL)
- **Last updated:** 2022-10-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04566770

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04566770, "A Clinical Trial of A COVID-19 Vaccine Named Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04566770. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*